Y-mAbs Therapeutics CFO Bo Kruse To Retire
(RTTNews) - Biopharmaceutical company Y-mAbs Therapeutics, Inc. (YMAB) announced Thursday that Chief Financial Officer Bo Kruse has notified the Company of his resignation. Y-mAbs has commenced a search process for a successor.
Kruse will remain in the CFO role until his successor is identified and joins the Company. He will then continue as a non-executive employee from the time his successor joins the Company through July 31, 2024. After that, he is expected to be available to the Company for a period of time to support a smooth transition of the CFO role.
Prior to joining the Company in June 2016, Kruse was the CFO of the Danish biotech company Azanta A/S from 2009 to 2015.
Further, Kruse served as Genmab A/S' Vice President and CFO from 2005 to 2008, and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005.
New York Manufacturing Index Unexpectedly Climbs To Nine-Month High In August
U.S. Consumer Sentiment Index Unexpectedly Decreases In August
U.S. Import Price Growth Exceeds Estimates In July
U.S. Retail Sales Climb 0.5% In July, In Line With Estimates
U.S. Industrial Production Edges Slightly Lower In July
New York Manufacturing Index Unexpectedly Increases In August
U.S. Import Prices Rise More Than Expected In July
